Top 20 Pharma and Biopharma Companies As expected, in 2023 sales for pharmaceutical companies making COVID-19 vaccines and treatments, including big names like Pfizer, took a nosedive.

Oct 1, 2024 · Calyx and Invicro have launched under a new corporate identity: Perceptive. The new name reflects the organization’s increased strengths and capabilities, as they consolidate their place as a leader in the provision of discovery, imaging, and eClinical solutions and services.

Apr 24, 2025 · PCI Pharma Services, a global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies, is acquiring an entire equity stake in Ajinomoto Althea Inc. (Althea), a U.S.-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co. Inc ...

Apr 29, 2025 · Granata Bio has acquired Oviva Therapeutics Inc., a women’s health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging. Oviva’s lead candidate, OVI-586, is a first-in-class therapeutic designed to enhance women’s health span—the ...

Apr 23, 2025 · Clients trust Douglas CDMO as a partner for its commitment to quality, transparency, and a seamless experience. The company has a proven track-record in offering end-to-end integrated drug development services, specializing in formulating and commercially supplying innovative and generic high-potency small molecule softgels and liquids.

Jan 27, 2025 · Dr. Amit Patel, Founder and Executive Lead, Corporate Development, Pharmanovia. Amit founded Pharmanovia (previously Atnahs) in 2013. He was formerly the CEO and now plays a critical role as Executive Lead for Corporate Development.

Apr 30, 2025 · The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease.

Feb 2, 2018 · Contract manufacturing organizations (CMOs) have been very active in mergers and acquisitions (M&A) in the last few years, driving consolidation among CMOs, but increasingly also acquiring manufacturing sites from Pharma companies.

Mar 17, 2025 · AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilizing Hybrozyme platform technology. AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialize subcutaneous formulations of several oncology assets ...

Mar 21, 2025 · Under this collaboration, AstraZeneca will gain access to Syneron Bio’s Synova platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform designed to support the advancements of research programs exploring possible future treatments of chronic diseases, including rare, autoimmune, and metabolic disease.